Enlivex Therapeutics Ltd.
NASDAQ: ENLV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Oren Hershkovitz
- Employees
- 71
- Headquarters
- Ness Ziona, Israel
- IPO year
- 2014
- Market cap
- $14.7M
- Website
- https://www.enlivex.com
Loading ENLV…
Loading profile data…Frequently asked questions about ENLV
What does Enlivex Therapeutics Ltd. (ENLV) do?
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in a...
Where does ENLV trade?
Enlivex Therapeutics Ltd. (ENLV) trades on the NASDAQ Capital Market.
What sector is ENLV in?
Enlivex Therapeutics Ltd. (ENLV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Enlivex Therapeutics Ltd.?
Oren Hershkovitz is the chief executive officer of Enlivex Therapeutics Ltd. (ENLV).
Where is Enlivex Therapeutics Ltd. headquartered?
Enlivex Therapeutics Ltd. is headquartered in Israel.
Does ENLV pay a dividend?
Enlivex Therapeutics Ltd. (ENLV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENLV go public?
Enlivex Therapeutics Ltd. (ENLV) completed its initial public offering in 2014.